Market Intelligence
AstraZeneca, Lilly, Novo Nordisk and Amgen all moved up in the rankings on the Scrip 100 leaderboard powered by impressive double-digit growth.
Six companies exceeded $20bn in the latest Top 100 ranking of global medtechs by revenues, but with a slew of structural changes ahead, the leader board could change in 2026.
The pharmaceutical industry continues to experience significant shifts in sales performance, with some companies achieving remarkable growth while others face stagnation or decline.
Executives leading the commercialization of cell and gene therapies are informing how the industry approaches everything from manufacturing strategy to physician education.
The verdict from the front lines of drug development is unmistakable: RWD and AI won’t transform trials through hype alone – they deliver only when welded to airtight data practices, transparent models and accountable operations.
As regulatory uncertainty under the Trump administration eases, with dealmaking picking up and biopharma firms delivering good data, financial markets are primed for biopharma investment.
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
Against a choppy macro backdrop, innovation dynamics have remained largely intact, as the industry continues to invest heavily into R&D.
French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
During Q3, biopharma merger and acquisition deal value reached $40.7bn and drew in $66.5bn in potential deal value from alliances. Device company M&A values reached $6.4bn, while in vitro diagnostics and research tools players’ M&A activity totaled $15m.
New York biotech OS Therapies reported 75% two-year survival in an osteosarcoma trial of its immunotherapy, OST-HER2. Leadership is targeting early 2026 approvals across three continents for what is the first new osteosarcoma treatment in 40 years.
In a busy year for US biosimilars, 2025 saw more than a dozen approvals as multiple biologics faced competition for the first time – including Stelara. However, concerns persist over the lack of rivals in development for numerous brands coming off-patent, with a hope that regulatory streamlining can
During Q3, biopharmas brought in an aggregate $20.1bn in financing and device company fundraising totaled $2.5bn; while in vitro diagnostic firms and research tools players raised $1.2bn.
The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.
The billion-dollar startup has doubled headcount, released massive datasets and is advancing therapeutics, but the hard part lies ahead.
In this episode of the In Vivo podcast, Sweden-based Cereno Scientific's CEO discusses how his company is turning to an old drug to help patients with rare cardiovascular and pulmonary diseases.
Eight $1bn+ alliances were penned in September, and four exceeded $2bn. In the top alliance by deal value, Monte Rosa Therapeutics will apply its AI-enabled QuEEN platform for the discovery and development of novel molecular glue degraders for immune-mediated diseases.
A new report highlighting 62 key drug launches expected in 2026 includes five products that are predicted to hit a golden trifecta of being a first launch, having practice-changing potential and the promise of being a blockbuster.